HPM.F : Summary for HORIZON PETROLEUM - Yahoo Finance

U.S. Markets closed

HORIZON PETROLEUM (HPM.F)


Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.02+0.00 (+25.00%)
At close: 4:45PM CET
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.02
Open0.02
Bid0.00 x 5000000
Ask0.00 x 2800000
Day's Range0.02 - 0.02
52 Week Range0.00 - 0.06
Volume16,300
Avg. Volume368
Market Cap1.55M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Horizon's Rare Disease Drug Quinsair Launched in Canada
    Zacks25 days ago

    Horizon's Rare Disease Drug Quinsair Launched in Canada

    Horizon Pharma plc (HZNP) announced the availability of Quinsair (levofloxacin inhalation solution) in Canada for the management of chronic pulmonary infections.

  • Barrons.com29 days ago

    Valeant Pharmaceuticals: A Trump Winner or Loser?

    Before the election, everyone assumed that a Donald Trump victory would be good for the healthcare sector due to less scrutiny from a Republican administration. Guggenheim's Louise Chen and team consider which companies could benefit--and which could face headwinds--under a Trump administration: We hosted meetings with Steve Pearson, the Founder and President of ICER (Institute for Clinical and Economic Review) on 12/15/16 to discuss what changes to expect in Pharma under the Trump Administration.

  • Market Realistlast month

    What Are Analysts Saying about Horizon Pharma?

    According to a Thomson Reuters Eikon consensus of six brokerage firms on December 17, 2016, 83.3% of the firms rated Horizon Pharma (HZNP) a “buy.”